Boston Life Sciences, Inc. (BLSI) - 500 Beiträge pro Seite

[gholzbauer]

Dies hier habe ich heute zufällig gefunden, und mich würde interessieren, ob jemand eine Meinung zu BLSI hat.


H.C. Wainwright & Co. Comments On Altropane Phase III Results and Reiterates BUY Recommendation
BOSTON, Jul 31, 2000 (BW HealthWire) -- Boston Life Sciences, Inc. (NASDAQ: BLSI chart, msgs) announced that H.C. Wainwright & Co. Healthcare Technology analyst Ronald Opel reiterated his BUY rating on Boston Life Sciences in a First Call notice released Friday morning. The report was issued following the Company`s recent announcement of its successful Phase III Altropane trial for the diagnosis of Parkinson`s Disease. A summary of the key points made in the First Call notice were:

Results from the multi-center Phase III study include 86% specificity, 75% sensitivity, and overall accuracy of 80%. The report noted that these results were far superior to those achieved by generally-approved radioimaging agents. The Phase III study was designed to confirm Altropane`s ability to differentiate Parkinson`s movement disorders (including Parkinson`s Disease (PD)) from other movement disorders. The Company`s previous Phase II clinical trial demonstrated Altropane`s efficacy in differentiating normal patients from those with PD.

To the best of H.C. Wainwright`s knowledge, there is no other diagnostic agent for Parkinson`s Disease in the U.S., either approved or in active clinical trials. The basis of all current PD diagnosis is behavioral, not biological. The report indicated that the Company is well positioned to capture a large majority share of the potential U.S. market for PD diagnostics, which is estimated to be approximately $100 - $125 million. The report noted that it is estimated that approximately 250,000 individuals report new, undiagnosed movement disorders to their physicians, most of whom are candidates for early PD diagnosis.

The report indicated that BLSI management and several large U.S. pharmaceutical companies were continuing discussions that could lead to a marketing and distribution agreement for Altropane. The report noted that a contract would probably not be finalized and announced until results of the currently active Phase II clinical trial for Altropane as a diagnostic for Attention Deficit Hyperactivity Disorder (ADHD) was completed, and the results determined. The potential ADHD market is several times larger than the PD market, and the current ADHD study outcome obviously should have a significant impact upon the contract terms. The report indicated that an Altropane marketing partner announcement would more likely occur during the first half of 2001, although there can be no assurances in that respect.

H. C. Wainwright & Co., Inc. founded in 1868 and based in Boston, is a leading source of high-quality equity research, investment banking, asset management, consulting, retail and institutional securities brokerage, and other financial advisory services. The firm`s strong background in equity research enables it to provide institutional and individual clients with accurate and up-to-date investment information and counsel.

BLSI is developing novel diagnostics and therapeutics for Parkinson`s Disease (PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments for cancer, autoimmune disease, and central nervous system disorders. BLSI`s products in development include: Altropane, a radioimaging agent for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies.

[gholzbauer]

Buy Rating On Boston Life Sciences Reiterated and Price Target Raised by H.C. Wainwright & Co.
BOSTON, Jun 30, 2000 (BW HealthWire) -- Boston Life Sciences, Inc. (NASDAQ: BLSI chart, msgs) announced that H.C. Wainwright & Co. Healthcare Technology analyst Ronald Opel had reiterated his BUY rating on Boston Life Sciences and increased his price target to $15. The update was provided in a First Call notice released yesterday afternoon.

The First Call report noted that the Company was increasing its research and development expenditure levels as a result of continued broad-based progress in its CNS (central nervous system) programs. Recent events include:

-- further groundbreaking discovery of a methodology (as published in the Journal of Neuroscience) to enhance regeneration of the optic nerve in BLSI`s glaucoma program;

-- initiation of a pre-clinical trial program to develop its nerve regeneration factor, Inosine, as therapy to induce functional recovery following stroke;

-- extension of pre-clinical studies to demonstrate that Inosine stimulates re-growth of severed spinal cord motor nerve fibers through the area of experimental injury;

-- commencement of a Phase II clinical trial in May for the use of Altropane as a diagnostic for Attention Deficit Hyperactivity Disorder (ADHD). The Company completed its Phase III clinical trial for the use of Altropane as a diagnostic for Parkinson`s Disease (PD) and expects to report results upon completion of statistical data compilation;

-- initiation of a program to develop therapeutic compounds (licensed from the same collaborating scientists who developed Altropane) for the treatment of PD and other CNS disorders;

-- filing of an IND and commencement of a Phase I trial to test the safety and efficacy of Fluoratec, a technetium-based "second-generation" imaging agent for the diagnosis of PD and ADHD


The increased expenditures associated with these expanded programs (as well as the ongoing program to prepare Troponin for human trials) are being funded, in part, by the proceeds of a $10 million common stock placement completed in June with the Pictet Global Sector Biotech Fund, a highly regarded Swiss-based fund with approximately $850 million in assets. The placement brought BLSI`s cash position to approximately $25 million.


About H.C. Wainwright & Co., Inc.
H.C. Wainwright & Co., Inc. founded in 1868 and based in Boston, is a leading source of high-quality equity research, investment banking, asset management consulting, retail and institutional securities brokerage, and other financial advisory services. The firm`s strong background in equity research enables it to provide institutional and individual clients with accurate and up-to-date investment information and counsel.

[puhvogel]

Da sprichst du mein aktuelles Sorgenkind an. Eigentlich sollte ich mich bei Altropane wirklich auskennen, grübel aber immer noch darüber nach, wie die Erfolgsaussichten wohl aussehen mögen.
Die Anleger waren zunächst mal enttäuscht, dass nicht die 99% prozentigen Trefferquoten wie bei der Phase 2 Studie erreicht wurden.
Das läßt sich aber leicht erklären, da dort PD gegen gesunde Probanden verglichen wurden.
In Phase 3 wurden dagegen PD-Patienten mit Patienten mit PD-ähnlichen Symptomen verglichen.
Zur Unterscheidung einer PD von einer nicht-PD gibt es allerdings nur einen Goldstandard, nämlich die histologische Probe.
Nun weigern sich bekanntlich Patienten oft, eine Hirnbiopsie durchführen zu lassen ;-) , so dass mit großer Wahrscheinlichkeit im Vorfeld einige irrtümlich diagnostizierte PD der falschen Gruppe zugeteilt worden sind. Das ist das Kernproblem von Altropane.
Wirklich gut ist, dass die eigentlich wichtige Größe, die Spezifität, so hoch ausgefallen ist, denn der übliche Kandidat für eine solche Untersuchung wäre ein junger Patient mit PD-ähnlichen Symptomen wie Michael J Fox. Durch eine Falschdiagnose PD würde man ihn von effektiven Behandlungsformen auschließen.
Die Preisfrage ist: Würde ein Neurologe, wenn er selber nicht sicher ist, eine nicht zu billige Diagnose mit Strahlenbelastung durchführen lassen, bei der man sich nur zu 86 %/80%/76% sicher sein kann? kann?
Schwierig zu beantworten, finde ich, da von Arzt zu Arzt individuell. Die Verkaufszahlen werden mit Sicherheit zögerlich anlaufen. Anzufügen wäre noch, dass SPECT außerdem den Nachteil hat , dass es nicht in jedem Krankenhaus zur Verfügung steht und das Guilford zur Zeit an einem ähnlichen Radiopharmaka in Phase3 probt, vermutlich auf die selben Schwierigkeiten stoßen wird.
ich persönlich warte erst einmal die Ergebnisse von der Phase 2 ADHD-Studie ab.

Hoffe, Dir ein wenig weitergeholfen zu haben
Der Puhvogel

[trendwatcher]

BLSI-Tageshöchstkurs heute: 414 Dollar ...
leider offenbar nur ein Computerfehler (Systemumstellung).

Auf solche Kurse (s.o.) müssen wir noch länger warten.

trendwatcher